The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook for Penumbra's stock in the short term. The price target of $265 could indicate where the analyst believes the stock price will move, but it doesn't necessarily mean a significant change in the stock's current price.